Our findings demonstrate that COX-2 expression in tumor tissue was an independent predictor of VEGF expression and MVD in NSCLC patients, and COX-2 may be a stimulator of tumor-associated VEGF activity in NSCLC tissue. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.